ReviewMolecules (Basel, Switzerland)2009
Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents.
Review in Molecules (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Challenges and Opportunities in the Oral Delivery of Recombinant Biologics.Pharmaceutics · 2023Review
- [β-GluInternational journal of molecular sciences · 2021Article
- Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
- The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?Frontiers in pharmacology · 2020Review
- Brain Delivery of Thyrotropin-Releasing Hormone via a Novel Prodrug Approach.Pharmaceutics · 2019Article
- Coenzyme Q10 Influences on the Levels of TNF-α and IL-10 and the Ratio of Bax/Bcl2 in a Menopausal Rat Model Following Lumbar Spinal Cord Injury.Journal of molecular neuroscience : MN · 2018Article
- Design and exploratory neuropharmacological evaluation of novel thyrotropin-releasing hormone analogs and their brain-targeting bioprecursor prodrugs.Pharmaceutics · 2013Article
- The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.American journal of Alzheimer's disease (Columbia, Mo.) · 2013Article
- Neurodegenerative Diseases: Multifactorial Conformational Diseases and Their Therapeutic Interventions.Journal of neurodegenerative diseases · 2013Review
- Inflammation & apoptosis in spinal cord injury.The Indian journal of medical research · 2012Review
- "All in the mind"? Brain-targeting chemical delivery system of 17β-estradiol (Estredox) produces significant uterotrophic side effect.Pharmaceutica analytica acta · 2012Article
- [Glu2]TRH dose-dependently attenuates TRH-evoked analeptic effect in mice.Brain research bulletin · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Prodrug design for brain delivery of small- and medium-sized neuropeptides was reviewed, focusing on thyrotropin-releasing hormone and structurally related peptides as examples. We have summarized our most important advances in methodology, as well as assessed the benefits and limitations of bioreversible chemical manipulation techniques to achieve targeting of the parent molecules into the central nervous system. The value of prodrug-amenable analogues as potential drug-like central nervous systems agents was highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.